ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.

As high expression level of growth arrest-specific 6 (GAS6) had an adverse effect on prognosis in acute myeloid leukemia (AML) patients, it is interesting to reveal the relationship between GAS6-mRNA level and the survival condition of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). We screened The Cancer Genome Atlas database and found 71 AML patients with GAS6-mRNA expression and received allo-HSCT treatments. We divided them into two groups based on the median expression of GAS6-mRNA. Patients with GAS6-mRNA (=36) seemed to have lower bone marrow (BM) blast (0.022), lower percentage of type M5 (0.034), lower percentage of inv(16)/CBFβ-MYH11 karyotype (0.020), and lower rate of good risk classification (0.005) than the group GAS6-mRNA ( 35). Higher expression level of GAS6-mRNA also brought higher RUNX1 mutations (0.003), MLL-PTD mutations (0.042), TP53 mutations (0.042), and lower NRAS/KRAS mutations (0.042). Univariate analyses showed that GAS6-mRNA was unfavorable for overall survival (OS) (0.044), as RUNX1 and WT1 also gave negative influences. Multivariate analyses confirmed that GAS6-mRNA cut down the event-free servival (EFS) and OS of AML patients with HSCT (0.029, 0.025). Our study indicated that higher expression of GAS6-mRNA related with adverse effects in AML patients with HSCT treatment.